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reasons (6%). Discontinuations due to adverse events were: 
brimonidine (44.7%), dorzolamide/timolol ﬁxed combination
(25.9%), travoprost (14.7%), bimatoprost (13.9%), timolol
(11.0%), latanoprost/timolol ﬁxed combination (8.6%), and
latanoprost (8.4%). CONCLUSIONS: Changes in treatment
were most often associated with efﬁcacy (failure to reach or
maintain target pressure) and adverse effects. Discontinuations
of therapy were greatest with brimonidine and lowest with
latanoprost. Latanoprost and latanoprost ﬁxed combination
exhibited fewer discontinuations as a result of adverse effects in
comparison to timolol or other prostaglandin monotherapies.
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OBJECTIVE: This study examines mean days between patients
reﬁlling their glaucoma prescriptions for latanoprost, travoprost,
and bimatoprost. METHODS: Patients with an initial NDC
pharmacy claim for the 2.5mL bottle of latanoprost, travoprost,
or bimatoprost between September, 2002 and December, 2002
were identiﬁed from a retail pharmacy database. Continuous 
eligibility was deﬁned by at least one claim for the same lipid
agent and bottle size one year later between October, 2003 and
December, 2003. The mean number of days between claims,
mean number of reﬁlls, the average cost per patient per year and
the annual reﬁll cost differences between cohorts were calcu-
lated. Due to limitations inherent in claims data analyses, efﬁ-
cacy data were not part of the analysis. RESULTS: The mean
number of days between reﬁlls for latanoprost was 47, for travo-
prost 53, and for bimatoprost 52. The among-group difference
was statistically signiﬁcant (p < 0.0001). The mean number of
reﬁlls per year was calculated to be 7.8, 6.9, and 7.0 for
latanoprost, travoprost, and bimatoprost, respectively. Based on
the mean number of reﬁlls, the average cost per patient per year
was $429.11 for travoprost, $434.70 for bimatoprost, and
$455.36 for latanoprost. The incremental reﬁll cost savings per
year for the latanoprost population (n = 79,820) would be
approximately $2 million by using bimatoprost or travoprost
instead of latanoprost. CONCLUSIONS: Both bimatoprost and
travoprost have higher average days between reﬁlls, suggesting
these two products may last longer than latanoprost. Conse-
quently, an additional reﬁll cost savings is realized by using
bimatoprost or travoprost over latanoprost.
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OBJECTIVES: It is estimated that 1.2 million cataract surgeries
are performed annually in the United States. Cataract patients
bilaterally implanted with monofocal intra-ocular lenses (M-
IOLs) often remain partially dependent on spectacles. Bilateral
implantation of apodized diffractive multifocal IOLs (ADM-
IOLs) substantially reduce postoperative spectacle dependence.
The objective of this study was to determine the value of the
ADM-IOL relative to the M-IOL based on patient willingness-
to-pay (WTP) for spectacle independence. METHODS: The eco-
nomic beneﬁt of spectacle independence was valued using a WTP
approach. The Cataract TyPE Speciﬁcation was used to collect
WTP for spectacle independence in a large clinical trial compar-
ing ADM-IOLs to M-IOLs. A cost-beneﬁt analysis (CBA) was
used to determine the net beneﬁt of spectacle independence for
ADM-IOL and M-IOL patients. Net beneﬁt was deﬁned as
patient WTP for spectacle independence, weighted by the prob-
ability of achieving spectacle independence, minus the incre-
mental cost of treatment. Cost information was taken from
standard reference sources and presented from a societal per-
spective. The incremental cost of the ADM-IOLs was set at
$1200. Costs and beneﬁts were discounted at 3%. The time-
frame of the study was 14 years based on patient life expectancy.
RESULTS: The clinical trial established that ADM-IOL patients
had an 80% probability of achieving spectacle independence
compared to only 8% for M-IOL patients. The vast majority of
the trial subjects (80%) indicated a daily WTP of ≥$5.00 for
spectacle independence. Based on these results, the ADM-IOL
net beneﬁt was estimated at $13,802 compared to a net beneﬁt
of $1,371 for the M-IOL. CONCLUSIONS: This study indicated
that cataract patients place a high value on spectacle indepen-
dence. Consequently, the net beneﬁt of the ADM-IOL was 11.5
times greater than its incremental cost and nine times greater
than the beneﬁt provided by the M-IOL.
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OBJECTIVES: Glaucoma is the second leading cause of bilateral
blindness worldwide. Early detection and treatment can prevent
the occurrence of blindness. The objective of this study is to
determine the most cost-effective case-ﬁnding strategy to detect
and treat ocular hypertension (OH) and primary open-angle
glaucoma (POAG) by the ophthalmologist to prevent blindness.
METHODS: An elevated intraocular pressure (IOP) deﬁnes 
OH and is a major risk factor for POAG. IOP is assessed by
tonometry. Three case-ﬁnding strategies, which differ with
respect to the group of patients receiving tonometry, are analyzed
and compared using a Markov cost-effectiveness model. All
patients undergo ophthalmoscopy to detect a glaucomatous
optic nerve, but tonometry is routinely performed to: 1) all newly
visiting patients; 2) high-risk patients only; or 3) no one. The
population characteristics are based on the literature and on data
gathered from the charts of 1000 new patients visiting an 
ophthalmic practice. Transition probabilities are taken from the
literature. The (direct) costs of diagnosis and treatment represent
those for The Netherlands. The time-horizon of the model is 
20 years. An annual discount rate of 4% is used. RESULTS:
Strategy three is cheapest but also yields most blindness. For
strategy one, the computed extra costs to prevent one person
from blindness amount to 7800€. For strategy two this is
19,500€. The marginal C/E ratio for strategy one is 1670€ per
year of vision saved; for strategy two this is 4250€. These out-
comes disregard extra costs due to blindness, estimated to exceed
at least 5000€ per year of blindness. Strategy one is computed
to become cost saving when such costs exceed 1700€. Extensive
sensitivity analyses show that these results are robust. CON-
CLUSION: It is cost-effective to routinely perform tonometry 
to all new ophthalmic patients to prevent blindness due to 
glaucoma.
